FDA Again Rejects Xarelto for ACS
The FDA delivered a second blow to the makers of rivaroxaban (Xarelto) in their bid to treat patients with acute coronary syndromes (ACS).
HPS2-THRIVE: High myopathy risk with niacin/laropiprant
New data shed some light on the adverse events associated with extended-release niacin and the antiflushing agent laropiprant in the Heart Protection Study 2-Treatment of HDL ...
Mediterranean Diets Beat Low-Fat for CVD Prevention
A Mediterranean diet supplemented with either extra virgin olive oil or mixed nuts may cut the risk of cardiovascular events by as much as 30% in subjects at high risk of developing heart disease...